Abbreviations: ISG15, interferon-stimulated gene 15; MTCO1, mitochondria complex 1; NEDD8, neural precursor cell expressed, developmentally down-regulated 8; PIASs, Protein inhibitor of activated STAT superfamily; PTM(s), Post-translational modification(s); RANBP2, RAN Binding Protein 2; SAE1/2, SUMO activating enzyme subunits ½; SENP(s), Sentrin-specific proteases; SUMO, Small Ubiquitin-like Modifier; SUMO E1, SUMO-activating enzyme E1; SUMO E2, SUMO-conjugating enzyme E2; SUMO E3, SUMO ligase E3; UBC9, Ubiquitin conjugating enzyme 9; ZNF451, Zinc Finger Protein 451. Abstract SUMOylation is a dynamic, reversible, enzymatic drug-targetable post-translational modification (PTM) reaction where the Small Ubiquitin-like Modifier (SUMO) moieties are attached to proteins. This reaction regulates various biological functions like cell growth, differentiation, and it is crucial for maintaining organ homeostasis.However, the actions of SUMO in skeletal muscle pathophysiology are still not investigated. In this study, we quantified the abundance of the SUMO enzymes and determined the distribution of SUMOylated proteins along the fibers of nine different muscles. We find that skeletal muscles contain a distinctive group of SUMO enzymes and SUMOylated proteins in relation to their different metabolism, functions, and fiber type composition. In addition, before the activation of protein degradation pathways, this unique set is quickly altered in response to muscle sedentariness.Finally, we demonstrated that PAX6 acts as an upstream regulator of the SUMO conjugation reaction, which can become a potential therapeutic marker to prevent muscle diseases generated by inactivity.